Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Immuncell-LC
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : GC Cell
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Rivaara Immune has obtained the exclusive right to develop and commercialize Immuncell-LC® within India for liver cancer.
Product Name : Immuncell-LC
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 01, 2022
Lead Product(s) : Immuncell-LC
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : GC Cell
Deal Size : Undisclosed
Deal Type : Licensing Agreement